Altered Expression of Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor Receptor‑1, Vascular Endothelial Growth Factor Receptor‑2, and Soluble Fms-like Tyrosine Kinase-1 in Peripheral Blood Mononuclear Cells from Normal and Preeclamptic Pregnancies

10.4103/CJP.CJP_15_19

Zaima Ali；Saba Khaliq；Saima Zaki；Hafiz Usman Ahmad；Khalid Pervaiz Lone

Angiogenesis ； normotensive pregnant women ； preeclampsia ； pregnancy ； soluble Fms-like tyrosine ； vascular endothelial growth factor

The Chinese Journal of Physiology

62卷3期（2019 / 06 / 30）

117 - 122

英文

Preeclampsia (PE) is the leading cause of maternal and fetal morbidity and mortality. It complicates around 2%-10% pregnancies worldwide due to imbalance between proangiogenic and anti-angiogenic factors, leading to incomplete placentation, ischemia, and endothelial dysfunction. The study was aimed to analyze the mRNA expression of vascular endothelial growth factor (VEGF) and its receptors, i.e., VEGF receptor-1 (VEGFR-1), VEGF receptor-2 (VEGFR-2), and soluble Fms-like tyrosine kinase-1 (sFlt-1) from maternal peripheral blood mononuclear cells (PBMCs) of PE patients. This was a cross-sectional comparative study comprising 18 normotensive and 18 PE patients; the patients were further divided as early-onset preeclampsia (EOP) and late-onset preeclampsia (LOP). The expression level of VEGF, its receptors (VEGFR-1 and VEGFR-2), and sFlt-1 was investigated using real-time polymerase chain reaction. There was a significant change in the mRNA expression with a decrease in VEGF, VEGFR-1, and VEGFR-2 and an increase in sFlt-1 in PBMCs of PE and normal pregnancies (P ＜ 0.001). sFlt-1 mRNA expression was increased by 2.95-fold in the PE group with an inverse correlation with expression of VEGFR-2 (Spearman's rho = 0.68). Based on these findings, we conclude that PE is associated with decrease in the mRNA expression of VEGF, VEGFR-1, and VEGFR-2 as compared to an increase in sFlt-1 in PBMCs.

1. Aardema, MW,Saro, MC,Lander, M,De Wolf, BT,Oosterhof, H,Aarnoudse, JG(2004).Second trimester Doppler ultrasound screening of the uterine arteries differentiates between subsequent normal and poor outcomes of hypertensive pregnancy: Two different pathophysiological entities?.Clin Sci,106,377-382.
2. Ahmed, A(2011).New insights into the etiology of preeclampsia: Identification of key elusive factors for the vascular complications.Thromb Res,127(Suppl 3),S72-S75.
3. Andraweera, PH,Dekker, GA,Laurence, JA,Roberts, CT(2012).Placental expression of VEGF family mRNA in adverse pregnancy outcomes.Placenta,33,467-472.
4. Can, M,Sancar, E,Harma, M,Guven, B,Mungan, G,Acikgoz, S(2011).Inflammatory markers in preeclamptic patients.Clin Chem Lab Med,49,1469-1472.
5. Chung, JY,Song, Y,Wang, Y,Magness, RR,Zheng, J(2004).Differential expression of vascular endothelial growth factor (VEGF), endocrine gland derived‑VEGF, and VEGF receptors in human placentas from normal and preeclamptic pregnancies.J Clin Endocrinol Metab,89,2484-2490.
6. Escudero, C,Celis, C,Saez, T,San Martin, S,Valenzuela, FJ,Aguayo, C(2014).Increased placental angiogenesis in late and early onset pre‑eclampsia is associated with differential activation of vascular endothelial growth factor receptor 2.Placenta,35,207-215.
7. Farina, A,Zucchini, C,Sekizawa, A,Purwosunu, Y,de Sanctis, P,Santarsiero, G(2010).Performance of messenger RNAs circulating in maternal blood in the prediction of preeclampsia at 10‑14 weeks.Am J Obstet Gynecol,203
8. Furuya, M,Kurasawa, K,Nagahama, K,Kawachi, K,Nozawa, A,Takahashi, T(2011).Disrupted balance of angiogenic and antiangiogenic signalings in preeclampsia.J Pregnancy,2011,123717.
9. Gille, H,Kowalski, J,Li, B,LeCouter, J,Moffat, B,Zioncheck, TF(2001).Analysis of biological effects and signaling properties of flt‑1 (VEGFR‑1) and KDR (VEGFR‑2). A reassessment using novel receptor‑specific vascular endothelial growth factor mutants.J Biol Chem,276,3222-3330.
10. Helske, S,Vuorela, P,Carpén, O,Hornig, C,Weich, H,Halmesmäki, E(2001).Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies.Mol Hum Reprod,7,205-210.
11. Hong, F,Li, Y,Xu, Y(2014).Decreased placental miR‑126 expression and vascular endothelial growth factor levels in patients with pre‑eclampsia.J Int Med Res,42,1243-1251.
12. Jia, H,Bagherzadeh, A,Bicknell, R,Duchen, MR,Liu, D,Zachary, I(2004).Vascular endothelial growth factor (VEGF)‑D and VEGF‑A differentially regulate KDR‑mediated signaling and biological function in vascular endothelial cells.J Biol Chem,279,36148-36157.
13. Kar, M(2014).Role of biomarkers in early detection of preeclampsia.J Clin Diagn Res,8,BE01-BE04.
14. Kim, SC,Park, MJ,Joo, BS,Joo, JK,Suh, DS,Lee, KS(2012).Decreased expressions of vascular endothelial growth factor and visfatin in the placental bed of pregnancies complicated by preeclampsia.J Obstet Gynaecol Res,38,665-673.
15. Levine, RJ,Maynard, SE,Qian, C,Lim, KH,England, LJ,Yu, KF(2004).Circulating angiogenic factors and the risk of preeclampsia.N Engl J Med,350,672-683.
16. Lu, F,Longo, M,Tamayo, E,Maner, W,Al‑Hendy, A,Anderson, GD(2007).The effect of over‑expression of sFlt‑1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice.Am J Obstet Gynecol,196
17. Maynard, SE,Min, JY,Merchan, J,Lim, KH,Li, J,Mondal, S(2003).Excess placental soluble fms‑like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.J Clin Invest,111,649-658.
18. Munaut, C,Lorquet, S,Pequeux, C,Coulon, C,Le Goarant, J,Chantraine, F(2012).Differential expression of vegfr‑2 and its soluble form in preeclampsia.PLoS One,7,e33475.
19. Nevo, O,Lee, DK,Caniggia, I.(2013).Attenuation of VEGFR‑2 expression by sFlt‑1 and low oxygen in human placenta.PLoS One,8,e81176.
20. Odegård, RA,Vatten, LJ,Nilsen, ST,Salvesen, KA,Austgulen, R(2000).Preeclampsia and fetal growth.Obstet Gynecol,96,950-955.
21. Okazaki, S,Sekizawa, A,Purwosunu, Y,Farina, A,Wibowo, N,Okai, T(2007).Placenta‑derived, cellular messenger RNA expression in the maternal blood of preeclamptic women.Obstet Gynecol,110,1130-1136.
22. Olszewska‑Pazdrak, B,Hein, TW,Olszewska, P,Carney, DH(2009).Chronic hypoxia attenuates VEGF signaling and angiogenic responses by downregulation of KDR in human endothelial cells.Am J Physiol Cell Physiol,296,C1162-C1170.
23. Osungbade, KO,Ige, OK(2011).Public health perspectives of preeclampsia in developing countries: Implication for health system strengthening.J Pregnancy,2011,481095.
24. Paiva, P,Whitehead, C,Saglam, B,Palmer, K,Tong, S(2011).Measurement of mRNA transcripts of very high placental expression in maternal blood as biomarkers of preeclampsia.J Clin Endocrinol Metab,96,E1807-E1815.
25. Rajakumar, A,Michael, HM,Rajakumar, PA,Shibata, E,Hubel, CA,Karumanchi, SA(2005).Extra‑placental expression of vascular endothelial growth factor receptor‑1, (Flt‑1) and soluble flt‑1 (sFlt‑1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women.Placenta,26,563-573.
26. Ren, Y,Wang, H,Qin, H,Yang, J,Wang, Y,Jiang, S(2014).Vascular endothelial growth factor expression in peripheral blood of patients with pregnancy induced hypertension syndrome and its clinical significance.Pak J Med Sci,30,634-637.
27. Takahashi, H,Shibuya, M(2005).The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions.Clin Sci,109,227-241.
28. Tripathi, R,Rath, G,Jain, A,Salhan, S(2008).Soluble and membranous vascular endothelial growth factor receptor‑1 in pregnancies complicated by pre‑eclampsia.Ann Anat,190,477-489.
29. Uzan, J,Carbonnel, M,Piconne, O,Asmar, R,Ayoubi, JM(2011).Pre‑eclampsia: Pathophysiology, diagnosis, and management.Vasc Health Risk Manag,7,467-474.
30. Wikström, AK,Larsson, A,Eriksson, UJ,Nash, P,Nordén‑Lindeberg, S,Olovsson, M(2007).Placental growth factor and soluble FMS‑like tyrosine kinase‑1 in early‑onset and late‑onset preeclampsia.Obstet Gynecol,109,1368-1374.
31. Young, BC,Levine, RJ,Karumanchi, SA(2010).Pathogenesis of preeclampsia.Annu Rev Pathol,5,173-192.
32. Zhou, Q,Liu, H,Qiao, F,Wu, Y,Xu, J(2010).VEGF deficit is involved in endothelium dysfunction in preeclampsia.J Huazhong Univ Sci Technolog Med Sci,30,370-374.
33. Zhou, Y,McMaster, M,Woo, K,Janatpour, M,Perry, J,Karpanen, T(2002).Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome.Am J Pathol,160,1405-1423.